|
22 Dec 2018 |
Kodiak Sciences Announces Completion of 12-Week Phase 1a Study of KSI-301 in Patients with Diabetic Macular Edema Demonstrating Safety and Durability of Responses Following Single Dose of Intravitreal Anti-VEGF Antibody Biopolymer Conjugate
|
|
22 Dec 2018 |
FDA Approves ELZONRIS (tagraxofusp), the First Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm and First CD123-Targeted Therapy
|
|
22 Dec 2018 |
Merck and Pfizer Provide Update on JAVELIN Ovarian 100 Trial of Avelumab in Previously Untreated Advanced Ovarian Cancer
|
|
22 Dec 2018 |
Alexion Receives Early FDA Approval for ULTOMIRIS™ (Ravulizumab-cwvz) in Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)
|
|
21 Dec 2018 |
Oxford BioTherapeutics Receives US FDA IND Clearance for OBT076
|
|
21 Dec 2018 |
Janssen Submits Application To U.S. FDA Seeking Approval Of STELARA® (ustekinumab) For Treatment Of Moderately To Severely Active Ulcerative Colitis
|
|
21 Dec 2018 |
CStone Pharmaceuticals announces initiation of CS1001 Phase I Study in U.S., patient enrollment under way
|
|
21 Dec 2018 |
OSE Immunotherapeutics Announces First Healthy Volunteers Dosed in Phase 1 Clinical Trial of OSE-127
|
|
21 Dec 2018 |
TRACON Pharmaceuticals Announces Top-line Data from Phase 2 TRAXAR Clinical Trial in Renal Cell Carcinoma
|
|
20 Dec 2018 |
Janssen Announces European Commission Approval of Darzalex (daratumumab) Split Dosing Regimen
|
|
20 Dec 2018 |
Chugai’s Satralizumab Meets Primary Endpoint in Phase III Monotherapy Study in NMOSD
|
|
20 Dec 2018 |
Chugai’s Satralizumab Receives FDA Breakthrough Therapy Designation for Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders
|
|
20 Dec 2018 |
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Adult and Pediatric Patients with Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma, a Rare Form of Skin Cancer
|
|
19 Dec 2018 |
I-Mab and CSPC Pharma Announce Strategic Partnership for Long-acting GLP-1 Fc Program
|
|
19 Dec 2018 |
NeuClone Announces its Sixth Biosimilar Candidate Perjeta(R) (Pertuzumab) for use in Combination Therapy with Herceptin(R) (Trastuzumab)
|
|
19 Dec 2018 |
BeiGene Initiates Two Global Phase 3 Front-Line Clinical Trials of Tislelizumab, in Patients with Gastric Cancer and in Patients with Esophageal Cancer
|
|
19 Dec 2018 |
Surface Oncology Resets Portfolio Priorities, Extends Cash Runway Through 2021
|
|
19 Dec 2018 |
Xbrane Biopharma has submitted the first application for start of Xlucane clinical trial
|
|
19 Dec 2018 |
Lilly announces positive top-line results for Taltz® (ixekizumab) vs. Humira® (adalimumab) in a head-to-head superiority study (SPIRIT-H2H) in patients with active psoriatic arthritis
|
|
17 Dec 2018 |
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Adults with Resected Stage III Melanoma
|
|
17 Dec 2018 |
Amgen Submits Biologics License Application for ABP 710 (Biosimilar Infliximab) To US Food And Drug Administration
|
|
15 Dec 2018 |
Celltrion and Teva Announce FDA Approval of HERZUMA® (trastuzumab-pkrb), a Biosimilar to HERCEPTIN®, for the Treatment of HER2-Overexpressing Breast Cancer for Certain Indications
|
|
15 Dec 2018 |
FDA Approves Nplate® (Romiplostim) For Use In Pediatric Patients With Immune Thrombocytopenia
|
|
14 Dec 2018 |
Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, ZIRABEV™ (bevacizumab)
|
|
14 Dec 2018 |
Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD
|
